← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Prokaryotics, Inc.
Union, NJ
$14,814,462
Total funding
10
Grants
Funding over time
peak $2.5M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,814,462 · 10
By mechanism
R44$11,252,175 · 5
R01$2,038,369 · 1
R21$929,000 · 3
R42$594,918 · 1
Investigators at Prokaryotics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections$1,000,000
R44 · FY2021 · AI
Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci$1,000,000
R44 · FY2019 · AI
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections$1,000,000
R44 · FY2022 · AI
Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci$1,000,000
R44 · FY2020 · AI
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci$999,396
R44 · FY2022 · AI
Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics$996,450
R44 · FY2025 · AI
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci$991,117
R44 · FY2023 · AI
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci$974,575
R44 · FY2024 · AI
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae$952,958
R44 · FY2019 · AI
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae$842,442
R44 · FY2020 · AI
Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis$679,683
R01 · FY2025 · AI
Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis$679,343
R01 · FY2024 · AI
Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis$679,343
R01 · FY2023 · AI
Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics$300,000
R44 · FY2022 · AI
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae$300,000
R44 · FY2018 · AI
Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci$299,999
R44 · FY2018 · AI
Development of an active site inhibitor of Fks1 as a broad spectrum antifungal agent$299,697
R44 · FY2025 · AI
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis$299,326
R42 · FY2023 · AI
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis$295,592
R42 · FY2024 · AI
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections$295,541
R44 · FY2019 · AI